ACTON, Mass. — Insulet Corporation has expanded the global reach of its Omnipod platform with the commercial launch of the Omnipod 5 Automated Insulin Delivery System in several Middle Eastern markets, including Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates.
The company announced the launch during the 16th Emirates Diabetes and Endocrine Congress in Dubai, marking a significant step in bringing tubeless automated insulin delivery technology to regions with high unmet needs in diabetes care. Alongside Omnipod 5, Insulet also introduced Omnipod Discover, a new data management and analytics platform designed to simplify diabetes data for users, caregivers, and healthcare providers.
“We’re proud to bring Omnipod 5 to a region where the unmet need is great,” said Pat Crannell, senior vice president and international general manager at Insulet. “These launches build on our significant momentum as we continue to transform the lives of people with diabetes worldwide. It is even more meaningful with the inaugural introduction of Omnipod Discover, which simplifies data management and helps create a world where diabetes demands less, every day.”
Omnipod 5 is designed to simplify diabetes management by automatically adjusting insulin delivery every five minutes based on continuous glucose monitoring data. Clinical studies have shown the system can improve time in range and lower HbA1c levels while eliminating the need for multiple daily insulin injections. The wearable, waterproof, and discreet system is the first tubeless automated insulin delivery platform that proactively helps correct high glucose levels and protect against lows around the clock.
In the newly launched markets, Omnipod 5 is indicated for individuals aged two years and older with type 1 diabetes. The system is compatible with the Abbott FreeStyle Libre 2 Plus and Dexcom G7 sensors in Saudi Arabia, Kuwait, and the UAE, and with the Dexcom G7 sensor in Qatar.
Insulet is also debuting Omnipod Discover in these Middle Eastern markets. The proprietary, web-based platform aggregates glucose and insulin delivery data and presents it in a simplified, intuitive format. The tool is designed to reduce the burden of data interpretation by transforming complex information into clear trends and actionable insights that support informed decision-making for both patients and clinicians.
Omnipod Discover allows users and healthcare providers to better understand how the Omnipod 5 algorithm automates insulin delivery and to identify meaningful patterns that can guide diabetes management. Insulet said the platform will be introduced in additional countries as Omnipod 5 expands globally.
With the latest launches, Omnipod 5 is now available in 19 countries worldwide. Insulet plans to expand availability further, including a launch in Spain in 2026, followed by Greece and Croatia in the first half of 2027.
Dr. Mohammed Almehthel, medical director and diabetes technology section head at the Obesity, Endocrinology and Metabolism Center at King Fahad Medical City in Saudi Arabia, said the introduction of Omnipod 5 represents a meaningful advancement for people living with type 1 diabetes in the region as standards of care increasingly embrace advanced technologies.
For families, the impact can be deeply personal. Khalid Al Shethri of Riyadh said his nine-year-old daughter, Yasmeen, recently began using Omnipod 5. “She’s a lively, brilliant girl, and diabetes has been something she’s had to think about every single day,” he said. “Now that school is such a big part of her life, it feels like a bit of her childhood is being given back, helping her feel freer and more confident.”
